Please use this identifier to cite or link to this item:
Title: [18F]-THK5351 PET Imaging in Patients With Semantic Variant Primary Progressive Aphasia.
Austin Authors: Lee, Hyon;Seo, Seongho;Lee, Sang-Yoon;Jeong, Hye Jin;Woo, Sung-Ho;Lee, Kyoung-Min;Lee, Yeong-Bae;Park, Kee Hyung;Heo, Jae-Hyeok;Yoon, Cindy W;Kang, Jae Myeong;Cho, Jaelim;Okamura, Nobuyuki;Furumoto, Shozo;Yanai, Kazuhiko;Na, Duk L;Ido, Tatsuo;Villemagne, Victor L ;Noh, Young
Affiliation: Departments of Neurology
Department of Neuroscience, College of Medicine
Neuroscience Center, Samsung Medical Center, Seoul, Republic of Korea
Departments of Neurology
Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine
Department of Health Science and Technology, GAIHST, Gachon University
Neuroscience Research Institute
Department of Neurology, Seoul National University Hospital
Department of Neurology, Seoul Medical Center
Department of Neurology, Inha University School of Medicine, Incheon
Occupational and Environmental Medicine, Gachon University Gil Medical Center
Cyclotron and Radioisotope Center, Tohoku University, Sendai, Japan
Department of Pharmacology, Tohoku Medical and Pharmaceutical University
Department of Molecular Imaging and Therapy, Centre for PET, Austin Health, Heidelberg, Victoria, Australia
The Florey Institute of Neuroscience and Mental Health, the University of Melbourne, Melbourne, Victoria, Australia
Issue Date: Jan-2018
Publication information: Alzheimer disease and associated disorders 2018; 32(1): 62-69
Abstract: Semantic variant primary progressive aphasia (svPPA) has been associated with a variety of proteinopathies, mainly transactive response DNA-binding protein, but also with tau and β-amyloid. Recently selective tau tracers for positron emission tomography (PET) have been developed to determine the presence of cerebral tau deposits in vivo. Here, we investigated the topographical distribution of THK5351 in svPPA patients. Five svPPA patients, 14 Alzheimer's disease patients, and 15 age-matched normal controls underwent [F]-THK5351 PET scans, magnetic resonance imaging, and detailed neuropsychological tests. [F]-fluorodeoxyglucose PET was obtained in 3 svPPA patients, whereas the remaining 2 underwent amyloid PET using [F]-flutemetamol. Tau distribution among the 3 groups was compared using regions of interest-based and voxel-based statistical analyses. In svPPA patients, [F]-THK5351 retention was elevated in the anteroinferior and lateral temporal cortices compared with the normal controls group (left>right), and in the left inferior and temporal polar region compared with Alzheimer's disease patients. [F]-THK5351 retention inversely correlated with glucose metabolism, whereas regional THK retention correlated with clinical severity. [F]-flutemetamol scans were negative for β-amyloid. These findings show that [F]-THK5351 retention may be detected in cortical regions correlating with svPPA pathology.
DOI: 10.1097/WAD.0000000000000216
Journal: Alzheimer disease and associated disorders
PubMed URL: 29028649
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Apr 19, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.